On November 17, 2025, Eli Lilly (LLY) shares declined after Novo Nordisk announced significant price reductions for its weight-loss drugs Wegovy and Ozempic, intensifying competition in the fast-growing obesity treatment market. Multiple sources report LLY stock fell between 1% and 2.3% following the news, despite the broader market also trading lower[3][4]. The price context confirms LLY is trading at $1,027.19 (+0.19%) as of early afternoon, after a strong multi-day rally. The competitive move by Novo Nordisk is seen as the primary reason for today's pullback, overshadowing otherwise positive sentiment and recent gains in LLY's share price.